Genocea Biosciences, Inc. (GNCA) Rating Reiterated by Cowen and Company
Cowen and Company reissued their outperform rating on shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) in a research note issued to investors on Tuesday morning. They currently have a $40.00 target price on the biotechnology company’s stock.
Several other equities analysts have also issued reports on the company. Piper Jaffray Companies reiterated an overweight rating and issued a $18.00 target price (up previously from $17.00) on shares of Genocea Biosciences in a research note on Tuesday. ValuEngine upgraded Genocea Biosciences from a sell rating to a hold rating in a research note on Monday, July 24th. Needham & Company LLC upgraded Genocea Biosciences from a hold rating to a buy rating and set a $12.00 target price on the stock in a research note on Monday, July 24th. Finally, Zacks Investment Research lowered Genocea Biosciences from a buy rating to a hold rating in a research note on Monday, July 17th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $16.52.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded up 1.15% during mid-day trading on Tuesday, hitting $6.16. 370,511 shares of the stock were exchanged. The firm’s market cap is $175.57 million. Genocea Biosciences has a 12 month low of $3.28 and a 12 month high of $7.29. The stock’s 50 day moving average is $5.33 and its 200 day moving average is $5.47.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.06. Analysts expect that Genocea Biosciences will post ($1.91) EPS for the current fiscal year.
WARNING: “Genocea Biosciences, Inc. (GNCA) Rating Reiterated by Cowen and Company” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/genocea-biosciences-inc-gnca-rating-reiterated-by-cowen-and-company/1461383.html.
In related news, CFO Jonathan Poole sold 45,000 shares of Genocea Biosciences stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the sale, the chief financial officer now owns 84,247 shares of the company’s stock, valued at $505,482. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.70% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. increased its stake in Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares during the period. Keybank National Association OH purchased a new stake in Genocea Biosciences during the first quarter worth approximately $147,000. Segantii Capital Management Ltd purchased a new stake in Genocea Biosciences during the first quarter worth approximately $160,000. JPMorgan Chase & Co. purchased a new stake in Genocea Biosciences during the first quarter worth approximately $217,000. Finally, Geode Capital Management LLC increased its stake in Genocea Biosciences by 4.7% in the first quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock worth $903,000 after buying an additional 6,708 shares during the period. 54.23% of the stock is owned by hedge funds and other institutional investors.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.